Precipio, Inc. (PRPO) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US74019L6020

Price
19.35 USD
Market cap
34.64 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Precipio, Inc. financials

Fiscal year2025
Revenue24.05 m USD
Gross profit10.71 m USD
Operating income-1.20 m USD
EBIT-363,000.00 USD
Net income-363,000.00 USD
Diluted EPS – continuing operations-0.23 USD

Full history since 1999, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Precipio, Inc.

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.